摘要
目的探讨糖化血红蛋白在非糖尿病冠心病患者中的应用价值。方法选取非糖尿病冠心病患者110例(急性冠脉综合征60例和稳定性心绞痛50例)以及非糖尿病非冠心病的其他病种50例,测定并比较各组糖化血红蛋白的水平。结果非糖尿病冠心病组糖化血红蛋白水平高于对照组(P<0.05),急性冠脉综合征组高于稳定性心绞痛组(P<0.05)。结论糖化血红蛋白是心血管风险的预测因子。
Objective To explore the clinical value of glycosylated hemoglobin （HbAt,） in non-diabetic coronary heart disease individuals. Methods One hundred and ten cases with non-diabetic coronary heart disease （CHD） including 60 cases with acute coronary syndrome （ACS） and 50 cases with stable angina peetoris （SAP）, and 50 cases of other diseases except diabetes and coronary heart disease were selected. The plasma levels of HbAl,, in all groups were de- tected and analyzed. Results The level of HbAh. in CHD group was significantly higher than that in control group （P 〈 0.05）, and level of HbAk, in ACS group was higher than that in SAP group （P 〈 0.05）. Conclusion HbAI,. is a markerof cardiovascular risk.
出处
《中国当代医药》
2013年第4期102-103,共2页
China Modern Medicine
关键词
糖化血红蛋白
非糖尿病
冠心病
急性冠脉综合征
Glycosylated hemoglobin
Non-diadetes
Coronary artery disease
Acute coronary syndrome
